CLINICAL_TRIALS
trial_result
· 2022-03-25
Clinical Trial Update: Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML [Phase 4]
Summary
Phase 4 trial update evaluating QTc, pharmacokinetics, and safety of gemtuzumab ozogamicin in CD33+ relapsed/refractory acute myeloid leukemia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: ECG, Pharmacokinetics | Phase 4 | Status: COMPLETED | Results posted: 2022-03-25